NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update




NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026.

Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two important forums. For NurExone, NANO.IL.2026 and Advanced Therapies represent two sides of the same innovation pathway – one focused on nano scale biology and delivery technologies, and the other on what it takes to translate them into a therapy built for consistent manufacturing, regulatory and clinical progress.”

NurExone will participate in NANO.IL.2026, an international nanoscience and nanotechnology conference and exhibition taking place in Jerusalem from March 8 to 10, 2026. Dr. Shaltiel will serve as an invited speaker in the Nano Biotech Industrial Approach track and as a co-chair of Nano Biotech Industrial Approach Part B. Exosomes size is at the nano scale, and NurExone’s platform is designed to develop them into minimally invasive regenerative therapies focused on central nervous system injuries.

In addition, Dr. Shaltiel will be speaking at the Advanced Therapies Congress in London in March 2026, Europe’s largest commercial cell and gene therapy conference and exhibition. The congress brings together global leaders in advanced therapeutics to address clinical translation, manufacturing scalability, commercialization, and investment trends.

Corporate Update

The Company announced that Mr. Jacob Licht will be stepping down from his roles as Chief Executive Officer of Exo-Top Inc. and Vice President, Corporate Development at NurExone at the end of March 2026 for personal reasons. The Company thanks Mr. Licht for his contributions and dedication and wishes him continued success. The Company’s management team will assume his responsibilities until further notice.

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Russo Partners LLC
Investor Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company’s anticipated participation in the conferences in March 2026; Dr. Shaltiel’s speaking at the conferences and participation in the panel discussions; the expected timing of Mr. Jacob Licht’s departure and the transition of his responsibilities; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the referenced conferences will proceed as scheduled; speaking engagements and participation will occur as currently planned; Mr. Licht’s transition and departure will occur on the expected timeline; the Company will be able to maintain continuity of its corporate development and subsidiary leadership functions through interim measures and/or additional personnel as required; that there will be no events or circumstances outside of the Company’s reasonable control that materially impact the foregoing; and the NurExone platform technology has the ability to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: changes to conference scheduling or programming; the availability of management and personnel; the risk that transitions in senior personnel take longer than anticipated or create operational disruption; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update




NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026.

Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two important forums. For NurExone, NANO.IL.2026 and Advanced Therapies represent two sides of the same innovation pathway – one focused on nano scale biology and delivery technologies, and the other on what it takes to translate them into a therapy built for consistent manufacturing, regulatory and clinical progress.”

NurExone will participate in NANO.IL.2026, an international nanoscience and nanotechnology conference and exhibition taking place in Jerusalem from March 8 to 10, 2026. Dr. Shaltiel will serve as an invited speaker in the Nano Biotech Industrial Approach track and as a co-chair of Nano Biotech Industrial Approach Part B. Exosomes size is at the nano scale, and NurExone’s platform is designed to develop them into minimally invasive regenerative therapies focused on central nervous system injuries.

In addition, Dr. Shaltiel will be speaking at the Advanced Therapies Congress in London in March 2026, Europe’s largest commercial cell and gene therapy conference and exhibition. The congress brings together global leaders in advanced therapeutics to address clinical translation, manufacturing scalability, commercialization, and investment trends.

Corporate Update

The Company announced that Mr. Jacob Licht will be stepping down from his roles as Chief Executive Officer of Exo-Top Inc. and Vice President, Corporate Development at NurExone at the end of March 2026 for personal reasons. The Company thanks Mr. Licht for his contributions and dedication and wishes him continued success. The Company’s management team will assume his responsibilities until further notice.

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”), OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar markets. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.

For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu

Russo Partners LLC
Investor Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company’s anticipated participation in the conferences in March 2026; Dr. Shaltiel’s speaking at the conferences and participation in the panel discussions; the expected timing of Mr. Jacob Licht’s departure and the transition of his responsibilities; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the referenced conferences will proceed as scheduled; speaking engagements and participation will occur as currently planned; Mr. Licht’s transition and departure will occur on the expected timeline; the Company will be able to maintain continuity of its corporate development and subsidiary leadership functions through interim measures and/or additional personnel as required; that there will be no events or circumstances outside of the Company’s reasonable control that materially impact the foregoing; and the NurExone platform technology has the ability to offer novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: changes to conference scheduling or programming; the availability of management and personnel; the risk that transitions in senior personnel take longer than anticipated or create operational disruption; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s Annual Information Form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call




Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Monday, March 16, 2026.

Weight Watchers will host a conference call to discuss results at 8:30 a.m. ET the same day. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

About Weight Watchers
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company’s filings with the United States Securities and Exchange Commission (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com

For media inquiries, please contact:
Lizzy Levitan
WW@hunt-gather.com

Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call




Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Monday, March 16, 2026.

Weight Watchers will host a conference call to discuss results at 8:30 a.m. ET the same day. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

About Weight Watchers
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company’s filings with the United States Securities and Exchange Commission (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com

For media inquiries, please contact:
Lizzy Levitan
WW@hunt-gather.com

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference




Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference

WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46^th Annual Health Care Conference, taking place March 2-4, 2026, in Boston.

Details for the Company’s participation are as follows:
     Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET

The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

Disclosure of a transparency notification from AOC Pharma S.à r.l.




Disclosure of a transparency notification from AOC Pharma S.à r.l.

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026.

Notification from AOC Pharma S.à r.l.

• On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its shareholding had crossed the 10% disclosure threshold downwards following a disposal of voting securities or voting rights attached to shares in Fagron.
• According to the notification, as of 18 February 2026, AOC Pharma S.à r.l. directly holds 7,274,291 shares in Fagron, corresponding to the same number of voting rights.
• Based on the total number of outstanding voting rights (73,668,904 as the applicable denominator), this shareholding represents 9.87% of the total voting rights.
• The notification was submitted by a parent undertaking or controlling person and sets out the full chain of controlled undertakings through which AOC Pharma S.à r.l. holds its shares.
• The full transparency notification from AOC Pharma S.à r.l. is available on the Fagron website via this link.

Further information
Ignacio Artola
Global Head of Investor Relations
investors@fagron.com

About Fagron
Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment

• 260227_AOC Pharma_notification

Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States




Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States

Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States

Irving, Texas, USA – February 27, 2026 – Atos, a global leader in AI-powered digital transformation, today announced it has been named a Leader by Information Services Group (ISG) in the 2025 ISG Provider Lens™ Cybersecurity – Services and Solutions report for the United States. Atos has been ranked a Leader in the ISG Provider Lens™ for cybersecurity in the U.S. for five consecutive years (2021–2025). This latest recognition reinforces Atos’ sustained leadership in the U.S. cybersecurity market.

Atos was recognized as a Leader in the following three key quadrants:

• Next-Generation SOC/Managed Detection & Response (MDR) Services
• Strategic Security Services
• Technical Security Services

The ISG Provider Lens™ 2025 report highlights the increasingly complex U.S. cybersecurity landscape, where organizations must manage sophisticated threat actors, expanding hybrid IT environments, and heightened regulatory requirements. ISG recognizes Atos for delivering integrated, end-to-end cybersecurity capabilities that combine advisory strength, advanced security operations, and deep technical expertise.

In the Strategic Security Services quadrant, ISG highlights Atos’ structured and results-oriented consulting approach, enabling enterprises to align cybersecurity strategies with business objectives while strengthening governance and compliance readiness.

Within Technical Security Services, the report underscores Atos’ expertise in hybrid cloud security, identity and access management, infrastructure protection, and regulatory alignment, noting its ability to execute large-scale transformations while maintaining operational continuity.

In the Next-Generation SOC/MDR Services quadrant, ISG emphasizes Atos’ AI-driven security operations model. The company leverages advanced analytics, automation, and multi-vector threat detection across endpoints, networks, cloud, and operational technology environments to provide 24/7 monitoring and rapid incident response.

According to the ISG Provider Lens 2025 report, Atos “demonstrates consistent strength in AI-led transformation, combining advanced expertise with structured practices across advisory, deployment and governance, positioning it as a disciplined, compliance-ready innovator.”

Michael Grunberg, Chief Executive Officer North America, Atos, said:

“Being recognized once again as a Leader in the United States by ISG is a strong validation of our cybersecurity strategy and our teams’ execution. U.S. organizations are navigating an increasingly complex threat environment while accelerating digital transformation. Atos helps clients strengthen resilience, modernize security operations, and align cybersecurity with business outcomes , ensuring they can innovate with confidence.”

Gowtham Sampth, Principal Analyst, ISG Provider Lens™, said:

“Atos exemplifies a forward-leaning cybersecurity advisory model based on technical depth and sector knowledge, transcending beyond compliance to help clients reshape their security postures against evolving digital risks and quantum disruption.”

With more than 6,500 cybersecurity experts worldwide and a global network of 17 Security Operations Centers (SOCs), Atos delivers comprehensive cybersecurity services spanning:

• Strategic advisory and governance
• Security testing and validation
• Hybrid cloud and identity security
• Operational technology (OT) protection
• Managed detection and response

Atos processes over 31 billion security events daily and supports more than 2,000 clients globally. Its AI-powered security operations model enables proactive threat mitigation, regulatory alignment, and scalable protection for enterprises across industries.

As cyber risks continue to evolve, Atos remains committed to helping organizations build secure digital foundations that support long-term growth, resilience, and innovation.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global, AI-driven technology research and advisory firm. With more than 1,600 professionals worldwide and over 900 clients — including 75 of the world’s top 100 enterprises — ISG supports organizations in navigating digital transformation and sourcing decisions.

ISG Provider Lens™ research combines data-driven market analysis with hands-on advisory expertise to deliver actionable insights on service providers and technology trends.

To access the complimentary report for the US, please use the link below.

ISG Provider Lens® 2025 for Cybersecurity – Services & Solutions in US

***

About Atos Group

Atos Group is a global leader in digital transformation with c. 63,000 employees and annual revenue of c. €8 billion, operating in 61 countries under two brands — Atos for services and Eviden for products. European number one in cybersecurity, cloud and high-performance computing, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is the brand under which Atos SE (Societas Europaea) operates. Atos SE is listed on Euronext Paris.

The purpose of Atos Group is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Press contact

Leonard Herbeck | leonard.herbeck@atos.net | 1-210-264-2247

Disclosure of a transparency notification from AOC Pharma S.à r.l.




Disclosure of a transparency notification from AOC Pharma S.à r.l.

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026.

Notification from AOC Pharma S.à r.l.

• On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its shareholding had crossed the 10% disclosure threshold downwards following a disposal of voting securities or voting rights attached to shares in Fagron.
• According to the notification, as of 18 February 2026, AOC Pharma S.à r.l. directly holds 7,274,291 shares in Fagron, corresponding to the same number of voting rights.
• Based on the total number of outstanding voting rights (73,668,904 as the applicable denominator), this shareholding represents 9.87% of the total voting rights.
• The notification was submitted by a parent undertaking or controlling person and sets out the full chain of controlled undertakings through which AOC Pharma S.à r.l. holds its shares.
• The full transparency notification from AOC Pharma S.à r.l. is available on the Fagron website via this link.

Further information
Ignacio Artola
Global Head of Investor Relations
investors@fagron.com

About Fagron
Fagron is the leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 35 countries around the world.

The Belgian company Fagron NV is based on Venecoweg 20A in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed through the Dutch company Fagron BV. Fagron BV’s head office is located in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Attachment

• 260227_AOC Pharma_notification

Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States




Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States

Atos named a Leader in ISG Provider Lens™ 2025 for Cybersecurity – Services and Solutions in the United States

Irving, Texas, USA – February 27, 2026 – Atos, a global leader in AI-powered digital transformation, today announced it has been named a Leader by Information Services Group (ISG) in the 2025 ISG Provider Lens™ Cybersecurity – Services and Solutions report for the United States. Atos has been ranked a Leader in the ISG Provider Lens™ for cybersecurity in the U.S. for five consecutive years (2021–2025). This latest recognition reinforces Atos’ sustained leadership in the U.S. cybersecurity market.

Atos was recognized as a Leader in the following three key quadrants:

• Next-Generation SOC/Managed Detection & Response (MDR) Services
• Strategic Security Services
• Technical Security Services

The ISG Provider Lens™ 2025 report highlights the increasingly complex U.S. cybersecurity landscape, where organizations must manage sophisticated threat actors, expanding hybrid IT environments, and heightened regulatory requirements. ISG recognizes Atos for delivering integrated, end-to-end cybersecurity capabilities that combine advisory strength, advanced security operations, and deep technical expertise.

In the Strategic Security Services quadrant, ISG highlights Atos’ structured and results-oriented consulting approach, enabling enterprises to align cybersecurity strategies with business objectives while strengthening governance and compliance readiness.

Within Technical Security Services, the report underscores Atos’ expertise in hybrid cloud security, identity and access management, infrastructure protection, and regulatory alignment, noting its ability to execute large-scale transformations while maintaining operational continuity.

In the Next-Generation SOC/MDR Services quadrant, ISG emphasizes Atos’ AI-driven security operations model. The company leverages advanced analytics, automation, and multi-vector threat detection across endpoints, networks, cloud, and operational technology environments to provide 24/7 monitoring and rapid incident response.

According to the ISG Provider Lens 2025 report, Atos “demonstrates consistent strength in AI-led transformation, combining advanced expertise with structured practices across advisory, deployment and governance, positioning it as a disciplined, compliance-ready innovator.”

Michael Grunberg, Chief Executive Officer North America, Atos, said:

“Being recognized once again as a Leader in the United States by ISG is a strong validation of our cybersecurity strategy and our teams’ execution. U.S. organizations are navigating an increasingly complex threat environment while accelerating digital transformation. Atos helps clients strengthen resilience, modernize security operations, and align cybersecurity with business outcomes , ensuring they can innovate with confidence.”

Gowtham Sampth, Principal Analyst, ISG Provider Lens™, said:

“Atos exemplifies a forward-leaning cybersecurity advisory model based on technical depth and sector knowledge, transcending beyond compliance to help clients reshape their security postures against evolving digital risks and quantum disruption.”

With more than 6,500 cybersecurity experts worldwide and a global network of 17 Security Operations Centers (SOCs), Atos delivers comprehensive cybersecurity services spanning:

• Strategic advisory and governance
• Security testing and validation
• Hybrid cloud and identity security
• Operational technology (OT) protection
• Managed detection and response

Atos processes over 31 billion security events daily and supports more than 2,000 clients globally. Its AI-powered security operations model enables proactive threat mitigation, regulatory alignment, and scalable protection for enterprises across industries.

As cyber risks continue to evolve, Atos remains committed to helping organizations build secure digital foundations that support long-term growth, resilience, and innovation.

About ISG

ISG (Information Services Group) (Nasdaq: III) is a leading global, AI-driven technology research and advisory firm. With more than 1,600 professionals worldwide and over 900 clients — including 75 of the world’s top 100 enterprises — ISG supports organizations in navigating digital transformation and sourcing decisions.

ISG Provider Lens™ research combines data-driven market analysis with hands-on advisory expertise to deliver actionable insights on service providers and technology trends.

To access the complimentary report for the US, please use the link below.

ISG Provider Lens® 2025 for Cybersecurity – Services & Solutions in US

***

About Atos Group

Atos Group is a global leader in digital transformation with c. 63,000 employees and annual revenue of c. €8 billion, operating in 61 countries under two brands — Atos for services and Eviden for products. European number one in cybersecurity, cloud and high-performance computing, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is the brand under which Atos SE (Societas Europaea) operates. Atos SE is listed on Euronext Paris.

The purpose of Atos Group is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Press contact

Leonard Herbeck | leonard.herbeck@atos.net | 1-210-264-2247

Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting




Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting

• Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting toxicities at three months 
• Early signals of functional and structural improvement observed at one month and three months

• 12-letter BCVA gain and 23% CST reduction observed in the treated eye at three months

• Full cohort data expected in mid-year 2026

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2026 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today new clinical data from its ongoing Phase 1/2 study of OPGx-BEST1 gene therapy, presented at the 49th Annual Meeting of the Macula Society, in San Diego, California.

The presentation, titled “Preliminary Results from an Adult Participant in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations,” reported 3-month results from the first (sentinel) adult participant treated in the study, highlighting positive safety, tolerability, and biological activity following subretinal administration of OPGx-BEST1.

The sentinel participant is a 63-year-old female with Autosomal-Recessive Bestrophinopathy (ARB) disease with severe functional impairment. The data demonstrated that OPGx-BEST1 was well tolerated with no ocular inflammation, no ocular or treatment-related adverse events, and no dose limiting toxicities. Early signals of functional vision improvement were observed, including an equivalent 12-letter gain in Best Corrected Visual Acuity (BCVA) in the treated study eye. In addition, structural improvement in central subfield thickness (CST) was observed with a 23% decrease in the study eye. Resolution of intraretinal fluid was also seen as early as 1-month in areas with less atrophy.

“We are encouraged by these results from our sentinel participant, showing OPGx-BEST1 was well-tolerated and demonstrated promising initial efficacy at three months,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. Although early, this data represents an important milestone for our OPGx-BEST1 program and for patients with BEST1-related retinal diseases.”

“BEST1-related retinal diseases represent a significant unmet medical need, with no approved treatments currently available,” said Mark Pennesi, M.D., Ph.D., study investigator at the Retina Foundation of the Southwest in Dallas, Texas. “The preliminary results from this study, including the early favorable safety profile and initial signals of functional and structural improvement, are encouraging and support continued evaluation of OPGx-BEST1 as a gene augmentation approach for patients with BEST1-associated disease.”

Recruitment in the Phase 1/2 study is ongoing at two clinical sites in the U.S., with additional sites expected to open in Florida, Cincinnati and New York. Two participants have been enrolled to date, with 3-month results from the full Cohort 1 expected in mid-year 2026.

The full presentation and video recording will be available on the Opus Genetics website in the Events section.

About OPGx-BEST1 and the Phase 1/2 Trial

OPGx-BEST1 leverages Opus Genetics’ proprietary AAV-based gene therapy platform, designed to deliver a functional copy of the BEST1 gene directly to the retinal pigment epithelium (RPE) cells where the defective gene resides. The program builds on extensive preclinical work demonstrating restoration of BEST1 protein expression and improved retinal function in relevant disease models.

By restoring BEST1 function, the therapy aims to address the underlying genetic cause of retinal degeneration and support preservation of photoreceptor health and visual function. BEST1-associated IRDs affect an estimated 22,000 patients worldwide and currently have no approved treatments.

The ongoing adaptive, open-label Phase 1/2 study is evaluating single-eye subretinal administration of OPGx-BEST1 up to two dose levels in adult participants with Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB). Treatment will be administered via a single subretinal injection in one eye of each participant with two dosing cohorts.

The primary objective is to assess safety and tolerability and identify the most appropriate dose for further clinical development, with participants followed longitudinally for long-term outcomes. The trial will also explore biological activity through functional and anatomical endpoints, including changes in visual function and retinal structure.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.   

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to the clinical development, clinical results, preclinical data, and future plans for Phentolamine Ophthalmic Solution 0.75%, OPGx-LCA5, OPGx-BEST1, RDH12, and earlier stage programs, and expectations regarding us, our business prospects, and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, our subsequent Quarterly Reports on Form 10-Q, and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “aim,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “strive,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics, Inc.